XOMA Royalty 将来の成長

Future 基準チェック /56

XOMA Royaltyは、78%と31.3%でそれぞれ年率78%で利益と収益が成長すると予測される一方、EPSはgrowで78.6%年率。

主要情報

78.0%

収益成長率

78.6%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	31.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	08 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:X0M1 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	49	3	N/A	N/A	3
12/31/2025	36	-7	N/A	N/A	3
12/31/2024	28	-6	N/A	N/A	3
9/30/2024	22	-35	-15	-15	N/A
6/30/2024	15	-24	-8	-8	N/A
3/31/2024	6	-42	-13	-18	N/A
12/31/2023	5	-46	-18	-18	N/A
9/30/2023	4	-32	-18	-18	N/A
6/30/2023	4	-31	-20	-20	N/A
3/31/2023	3	-30	-14	-17	N/A
12/31/2022	6	-23	-13	-13	N/A
9/30/2022	40	10	42	22	N/A
6/30/2022	41	10	36	22	N/A
3/31/2022	41	12	36	23	N/A
12/31/2021	38	8	23	23	N/A
9/30/2021	30	1	-11	10	N/A
6/30/2021	29	6	-3	10	N/A
3/31/2021	29	6	-2	11	N/A
12/31/2020	29	9	10	10	N/A
9/30/2020	2	-13	-12	-12	N/A
6/30/2020	11	-9	-18	-5	N/A
3/31/2020	11	-10	-25	-6	N/A
12/31/2019	18	-2	-20	0	N/A
9/30/2019	20	-2	-18	1	N/A
6/30/2019	12	-8	-27	-5	N/A
3/31/2019	13	-6	-21	-6	N/A
12/31/2018	5	-13	-28	-13	N/A
9/30/2018	9	-11	-30	-15	N/A
6/30/2018	44	9	N/A	18	N/A
3/31/2018	53	18	N/A	13	N/A
12/31/2017	53	6	N/A	3	N/A
9/30/2017	48	-11	N/A	15	N/A
6/30/2017	12	-39	N/A	-28	N/A
3/31/2017	2	-61	N/A	-32	N/A
12/31/2016	6	-54	N/A	-34	N/A
9/30/2016	53	-11	N/A	-12	N/A
6/30/2016	55	1	N/A	-19	N/A
3/31/2016	57	-7	N/A	-23	N/A
12/31/2015	55	-21	N/A	-31	N/A
9/30/2015	12	-53	N/A	-77	N/A
6/30/2015	15	-67	N/A	-74	N/A
3/31/2015	18	-55	N/A	-74	N/A
12/31/2014	19	-38	N/A	-78	N/A
9/30/2014	27	-83	N/A	-68	N/A
6/30/2014	28	-99	N/A	-65	N/A
3/31/2014	29	-104	N/A	-60	N/A
12/31/2013	35	-124	N/A	-46	N/A

アナリストによる今後の成長予測

収入対貯蓄率: X0M1は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1% ) よりも高い成長率であると考えられます。

収益対市場: X0M1今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: X0M1今後 3 年以内に収益を上げることが予想されます。

収益対市場: X0M1の収益 ( 31.3% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: X0M1の収益 ( 31.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: X0M1の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

XOMA Royalty 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Recent updates

Third quarter 2024 earnings released: US$1.59 loss per share (vs US$0.60 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: EPS: US$1.37 (vs US$0.59 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.86 loss per share (vs US$0.98 loss in 1Q 2023)

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.48 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.98 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings released: US$1.50 loss per share (vs US$0.69 profit in FY 2021)

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment improved over the past week

Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.51 loss in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.31 loss in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings released: US$0.32 loss per share (vs US$0.70 loss in 1Q 2021)

Investor sentiment deteriorated over the past week

XOMA Corporation, Annual General Meeting, May 18, 2022

Now 22% undervalued

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

CEO & Director recently sold €254k worth of stock

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

Full year 2020 earnings released: EPS US$0.82 (vs US$0.23 loss in FY 2019)

Revenue beats expectations

New 90-day high: €29.32

XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement

Revenue misses expectations

Third quarter 2020 earnings released: US$0.098 loss per share

New 90-day high: €20.84

XOMA Corporation Earns $25 Million Milestone Payment

XOMA Corporation announced that it has received $1.4 million in funding from Rezolute, Inc.

New 90-day high: €17.92

XOMA Corporation to Report Q2, 2020 Results on Aug 06, 2020

Earnings released

New 90-day low - €14.03

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘